2011 Reaxys PhD Prize opens for entries
Global competition for PhD students of chemistry
The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach.
Three prizewinners will each receive US$2,000 and will be invited to present their research at the Winners’ Symposium during the 14th Asian Chemical Congress, which takes place from 5–8 September in Bangkok, Thailand.
David Evans, scientific affairs director at Elsevier Properties, said: ‘The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself.’
He continued: ‘In 2010 we received more than 300 submissions from around the world covering the breadth of modern chemistry. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011.’
All entries will be evaluated by a review board of leading international chemists, chaired by the Professor A G M Barrett, Imperial College London, UK; Professor B M Trost, Stanford University, US; and Professor H N C Wong, Chinese University of Hong Kong, China, who are members of the Reaxys Advisory Board.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by 28 February to the Reaxys PhD Prize website.
Elsevier Properties SA a division of scientific publisher Reed Elsevier that manages intellectual property. It owns the PharmaPendium, Beilstein and Reaxys databases.
You may also like
Research & Development
OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial
OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development
Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss
Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory
Johnson & Johnson files FDA application for IMAAVY in wAIHA
Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development
Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies
Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development
SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration
A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer